A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
This research is testing a new medicine called Voxzogo for children who have hypochondroplasia, a condition that can affect how bones grow and lead to shorter stature. It's a 'Phase 3' study, meaning it's one of the final steps before a medicine might become widely available. Doctors are giving some children Voxzogo and others a 'dummy' medicine (placebo) to see if Voxzogo helps them grow taller over 52 weeks. They will carefully check the children's growth and whether the medicine causes any side effects. This helps researchers understand if Voxzogo is both effective and safe for children with hypochondroplasia.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about a medical condition called hypochondroplasia. Children with this condition can experience slower bone growth, which results in shorter stature. Doctors and researchers are looking for better ways to help children grow as much as they can. This particular study is testing a new medicine, which has the brand name Voxzogo, to see if it specifically helps children with hypochondroplasia grow taller.
To make sure the study results are fair and accurate, some children will receive the Voxzogo medicine, while others will receive a 'placebo.' A placebo looks just like the real medicine but contains no active ingredients – it’s like a dummy treatment. This helps the researchers compare the two groups to see if the real medicine is actually making a difference. Neither the children, their families, nor the doctors will know who is getting the real medicine and who is getting the placebo until the study is over.
The main goal is to find out if children taking Voxzogo grow more over a year than those taking the placebo. Researchers will carefully measure how much the children grow and also track any side effects to make sure the medicine is safe. This information is very important for deciding if Voxzogo could be a useful new treatment option for children with hypochondroplasia.
النقاط الرئيسية
- Tests a new medicine (Voxzogo) for children with hypochondroplasia.
- Compares Voxzogo to a dummy medicine (placebo) to see if it helps children grow.
- Called a 'Phase 3' study, an important step before a medicine can be approved.
- Study lasts about one year, with regular clinic visits.
- Aims to check both height growth and safety of the medicine.
من قد يكون مؤهلاً؟
This study is open to both boys and girls of all ages. To find out if your child can take part, doctors will need to check some specific health details. They will look at your child's medical history and current health to make sure the study is a safe and suitable option for them.
Even though the age range is wide, there will be other important checks. These might include reviewing other health conditions your child has, medicines they are currently taking, or other specific measurements to ensure they meet the study’s requirements.
It’s important to remember that not everyone with hypochondroplasia will be able to join. These checks are there to protect your child and to make sure the study results are clear and reliable. The study doctors will discuss all the requirements with you in detail.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Is my child diagnosed with hypochondroplasia?
- Is my child available for regular clinic visits for about a year?
- Am I comfortable with my child potentially receiving a placebo?
- Are we able to discuss all current medicines and health conditions with the study doctors?
- Am I willing to support my child with regular injections if required?
ماذا يتضمن المشاركة؟
If your child takes part in this study, they will receive either the study medicine (Voxzogo) or a placebo (dummy medicine) through an injection. This will happen regularly over a period of 52 weeks, which is about one year. You will have regular visits to the clinic so doctors can check your child's health, measure their growth carefully, and see how they are getting on.
During these visits, your child might have blood tests, physical examinations, and other assessments to track their progress and monitor for any changes. The doctors will explain exactly what each visit involves and how often your child will need to attend. After the 52 weeks of treatment, there will likely be some follow-up visits to continue checking your child's long-term health.
The total time your child will be involved in the study, including follow-up, will be clearly explained by the study team before you decide to take part.
المخاطر والفوائد المحتملة
المواقع (4)
- —غير مؤكدإسبانيا
- —غير مؤكدألمانيا
- —غير مؤكدإيطاليا
- —غير مؤكدفرنسا
أسئلة شائعة
What is hypochondroplasia?
Hypochondroplasia is a condition that affects how bones grow, leading to shorter limbs and stature. It's not usually painful and doesn't affect intelligence.
ما هي دراسة 'المرحلة 3'؟
Phase 3 is an important stage where a medicine is tested on a larger group of people to confirm it works well and is safe, before it can be approved for general use.
ما هو "العلاج الوهمي"؟
A placebo is a 'dummy' treatment that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the real medicine's effects.
Will my child know if they are getting the real medicine or the placebo?
No, neither your child nor the doctors will know who is getting which. This is called 'double-blind' and helps ensure the study results are fair.
How long will the study treatment last?
The main treatment period for the study medicine or placebo will last for 52 weeks, which is about one year.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.